Initiate Jardiance (Empagliflozin) in T2DM Patients Regardless of Albuminuria Level
Jardiance should be initiated in patients with type 2 diabetes and eGFR ≥20 mL/min/1.73 m² regardless of albuminuria level, including those with normal albumin excretion (UACR <30 mg/g). The presence or absence of albuminuria should not determine whether to start this medication.
Evidence-Based Initiation Criteria
Primary Indication (Strongest Evidence)
- eGFR threshold: ≥20 mL/min/1.73 m² 1, 2
- No albuminuria requirement: Effective across all UACR levels 3, 1
FDA-Approved Dosing Parameters
According to the FDA label, do not initiate Jardiance if eGFR is below 45 mL/min/1.73 m² for glycemic control 4. However, this FDA restriction is outdated compared to current guideline evidence.
Current Guideline Recommendations Override FDA Label
The 2025 KDOQI and 2022 KDIGO guidelines supersede the FDA label restrictions 1, 2:
- Initiate at eGFR ≥20 mL/min/1.73 m² for kidney and cardiovascular protection
- Continue therapy even if eGFR falls below 20 mL/min/1.73 m² once started 1, 2
Albuminuria Does NOT Determine Initiation
All UACR Categories Benefit Equally
The EMPA-KIDNEY trial definitively showed empagliflozin slows CKD progression across all albuminuria levels 5:
- UACR <30 mg/g (normoalbuminuria): 86% relative reduction in chronic eGFR slope
- UACR 30-300 mg/g (microalbuminuria): Significant benefit
- UACR >300 mg/g (macroalbuminuria): 29% relative reduction in chronic eGFR slope
The absolute benefit was smaller in normoalbuminuric patients because they progress more slowly, but the relative benefit was actually largest in those without albuminuria 5.
Guideline Consensus on Albuminuria
2022 ADA-KDIGO Consensus: Recommends SGLT2i for T2DM with eGFR ≥20 mL/min/1.73 m² with "urine albumin ranging from normal to 200 mg/g creatinine" 3
2025 KDOQI Guidelines 1:
- Strong recommendation (1A): eGFR ≥20 mL/min/1.73 m² with UACR ≥200 mg/g OR heart failure (any UACR)
- Moderate recommendation (2B): eGFR 20-45 mL/min/1.73 m² with UACR <200 mg/g
Practical Initiation Algorithm
Step 1: Check eGFR
- eGFR ≥20 mL/min/1.73 m²: Proceed to initiation
- eGFR <20 mL/min/1.73 m²: Do not initiate (but continue if already on therapy)
Step 2: Assess Volume Status
- Correct volume depletion before starting 6
- Consider reducing diuretics in patients at high risk for hypovolemia 6
Step 3: Initiate Therapy
- Starting dose: 10 mg once daily 4
- May increase to 25 mg daily for additional glycemic control (though glucose-lowering effect diminishes at lower eGFR) 6
Step 4: Monitor Initial Response
- Expect acute eGFR dip of 2-3 mL/min/1.73 m² in first 2 months 5, 2
- This is hemodynamic, reversible, and NOT a reason to discontinue 1, 2
- Continue therapy through this dip—long-term kidney protection follows 5
Common Pitfalls to Avoid
Pitfall #1: Withholding Due to Lack of Albuminuria
Wrong approach: "Patient has UACR 15 mg/g, so no need for SGLT2i"
Correct approach: Albuminuria status is irrelevant for initiation decision. The EMPA-KIDNEY trial showed benefit even in normoalbuminuric patients 5. Initiate based on eGFR ≥20 mL/min/1.73 m² alone.
Pitfall #2: Stopping Due to Initial eGFR Decline
The acute 2-3 mL/min/1.73 m² eGFR drop in the first 2 months is expected and protective 5, 2. After this initial dip, empagliflozin halves the chronic rate of eGFR decline (from -2.75 to -1.37 mL/min/1.73 m² per year) 5.
Pitfall #3: Following Outdated FDA Label Restrictions
The FDA label states not to initiate below eGFR 45 mL/min/1.73 m² 4, but this contradicts current evidence-based guidelines 1, 2. The EMPA-KIDNEY trial included patients with eGFR as low as 20 mL/min/1.73 m² and demonstrated clear benefit 5.
Pitfall #4: Discontinuing When eGFR Falls Below Initiation Threshold
Once started, continue empagliflozin even if eGFR drops below 20 mL/min/1.73 m² until dialysis initiation 1, 2. The CREDENCE and DAPA-CKD trial protocols specifically continued therapy below initiation thresholds 6.
Safety Considerations
Risk Mitigation Strategies 6, 2
Genital mycotic infections: Counsel on hygiene; occurs in ~6% vs 1% placebo 6
Euglycemic ketoacidosis:
- Maintain at least low-dose insulin in insulin-requiring patients
- Withhold during illness, surgery, or prolonged fasting 2
- Educate on sick-day protocol 6
Hypoglycemia: Reduce insulin or sulfonylurea doses proactively 6
Volume depletion: Monitor in elderly, those on diuretics, or with low baseline blood pressure 6
Monitoring After Initiation
- Do not increase frequency of eGFR monitoring due to SGLT2i initiation 1
- The reversible eGFR decrease is expected and generally not an indication to discontinue 2
- Continue standard CKD monitoring intervals
Bottom Line
Initiate Jardiance in all T2DM patients with eGFR ≥20 mL/min/1.73 m² regardless of UACR level. The drug provides kidney and cardiovascular protection across the entire spectrum of albuminuria, from normoalbuminuria to macroalbuminuria 5, 1. Albuminuria should not be used as a gatekeeper for SGLT2i therapy 5.